First GCP Study Published

First GCP Study Published

RYE, N.Y.--Maypro Industries announced the firstpublication of a study on Genistein Combined Polysaccharide (GCP), acombination of genistein and polysaccharide from basidiomycetes that grow in avariety of mushrooms. The study, "Regression of prostate cancer followingadministration of Genistein Combined Polysaccharide (GCP), a nutritionalsupplement: A case report," was published in the August issue of TheJournal of Alternative and Complementary Medicine (8, 4:493-8, 2002) (www.liebertpub.com/ACM/default1.asp).

Aaron Katz, M.D., lead author of the study, director of theCenter for Holistic Urology at Columbia Presbyterian Medical Center and medicaldirector for the U.S. GCP Research Association, discussed a case report of apatient with biopsy-proven prostate cancer who exhibited clinical andpathological evidence of regression following GCP administration. The patientwas enrolled in an Institutional Review Board-approved protocol and received GCPfor six weeks prior to radical prostatectomy. The patient's prostate specificantigen (PSA, a marker for prostate cancer) decreased after 44 days of low-doseGCP supplementation. No cancer was identified in the radical prostatectomyspecimen, and no side effects were observed in the patient.

Amino Up Chemical Co., based in Sapporo, Japan, owns thetrademark for GCP and Maypro, based in Purchase, N.Y., distributes the rawmaterial.